IL17A and psoriasis: For moderate to severe psoriasis, several monoclonal antibodies have been approved for the treatment, including tumor necrosis factor-α (TNF-α) inhibitors, an anti-interleukin (IL)-12/23 antibody, anti-IL-23 agents, an IL-17 receptor blocker, and IL-17A inhibitors.